Deans' stroke musings: Mobia Medical (MOBI) Reports Promising Two-Year Results from VNS-REHAB Study

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, July 15, 2026

Mobia Medical (MOBI) Reports Promising Two-Year Results from VNS-REHAB Study

In the US you would have long ago been kicked out of doctor and therapist supervised rehab due to plateauing. The goal is to kick you out of insurance as soon as possible to increase insurance company profits; it has nothing to do with getting you recovered! You'll have to ask for this while since in acute stage.

Mobia Medical (MOBI) Reports Promising Two-Year Results from VNS-REHAB Study

On July 14, 2026, Mobia Medical MOBI +2.16%

revealed encouraging two-year follow-up outcomes from the VNS-REHAB study, recently published in the peer-reviewed journal Neurology. The results indicate significant and sustained improvements in upper-limb motor function, daily living activities, and overall quality of life for patients who underwent the Vivistim Paired VNS Therapy. This study provides robust longitudinal evidence for interventions aimed at chronic ischemic stroke recovery.

Market Cap: $384.7 million
GF Score™: 7/100, indicating a below-average ranking in terms of long-term investment potential.
Insider Activity: There were 10 insider buying transactions over the past 3 months, with a total of 1,448,202 shares bought.

What's Behind the News?

The VNS-REHAB study results are significant as they showcase the efficacy of the Vivistim Paired VNS Therapy in improving motor functions and quality of life for stroke survivors. The study analyzed data from 49 participants and found that 76% achieved clinically meaningful responses on key assessments, including the Fugl-Meyer Assessment of Upper Extremity impairment and the Wolf Motor Function Test. These findings suggest that the therapy not only aids in physical rehabilitation but also enhances daily living activities and overall well-being, making it a promising option for chronic ischemic stroke recovery.

Lottery

Mobia Medical Inc operates in the healthcare sector, specifically within the medical devices and instruments industry. The company is focused on redefining stroke recovery for survivors living with motor impairments. Its flagship product, the Vivistim Paired Vagus Nerve Stimulation system, is primarily sold to stroke centers across the United States. With a market capitalization of $384.7 million, Mobia Medical continues to innovate in a critical area of healthcare, addressing the needs of stroke survivors.